Praluent Cost in Wisconsin 2026: Prices, Insurance, Medicaid, and Compounding

What Is Praluent (Alirocumab) and Why Does It Cost So Much?

Praluent is a fully human monoclonal antibody that inhibits PCSK9, a protein that degrades LDL receptors in the liver. By blocking PCSK9, alirocumab raises the number of functional LDL receptors and lowers circulating LDL cholesterol by 45 to 60 percent in most patients [1]. The drug is manufactured through a complex biologic production process, which is the primary reason its list price sits near $580 per month in 2026, consistent with the broader biologic drug category.

Alirocumab received FDA approval in July 2015 for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) requiring additional LDL-C lowering beyond maximally tolerated statin therapy [2]. Two available doses, 75 mg/mL and 150 mg/mL, are each injected subcutaneously every two weeks using a prefilled pen or syringe.

The ODYSSEY OUTCOMES trial enrolled 18,924 patients with recent acute coronary syndrome (ACS) and demonstrated that alirocumab 75 to 150 mg every two weeks reduced the composite of coronary heart disease death, nonfatal MI, ischemic stroke, or unstable angina requiring hospitalization by 15 percent compared with placebo (hazard ratio 0.85 to 95% CI 0.78 to 0.93, P<0.001) [3]. That cardiovascular outcome benefit justifies clinician advocacy for insurance coverage and helps patients make the case for prior authorization.

No FDA-approved generic version of alirocumab exists as of January 2026. Biosimilars follow a separate regulatory pathway under the Biologics Price Competition and Innovation Act, and no alirocumab biosimilar has received FDA clearance [4]. That absence keeps cash-pay prices high across all Wisconsin pharmacies.

Praluent List Price and Cash-Pay Costs in Wisconsin in 2026

The 2026 wholesale acquisition cost (WAC) for Praluent runs approximately $580 per month for either the 75 mg or 150 mg dose. Retail pharmacy cash-pay prices across Wisconsin cities, Milwaukee, Madison, Green Bay, Racine, track close to this WAC because no generic competition exists to push prices down [5].

A single auto-injector pen retails for about $290. Most patients use two pens per month (one injection every two weeks), putting the typical monthly spend at $580 without insurance or assistance programs.

GoodRx and similar discount platforms do not reliably produce meaningful savings on biologic drugs like Praluent. Discount coupons typically apply to small-molecule generic drugs where pharmacy margins allow deeper discounts. Wisconsin patients paying cash for Praluent should focus on the manufacturer savings card and 503A compounding options described below rather than coupon aggregators.

Specialty pharmacies such as CVS Specialty, Walgreens Specialty, and Accredo distribute Praluent in Wisconsin. Some offer 90-day supplies, though the per-dose price does not decrease substantially with volume because the drug's cost structure is tied to biologic manufacturing, not dispensing volume [6].

Wisconsin Medicaid Coverage for Praluent

Wisconsin Medicaid (ForwardHealth) covers alirocumab for qualifying members, but prior authorization (PA) is required in every case. The program does not auto-approve Praluent at the pharmacy counter.

To obtain PA approval under Wisconsin ForwardHealth, prescribers generally need to document: a confirmed diagnosis of HeFH or established clinical ASCVD, a trial of maximally tolerated statin therapy for at least 90 days, LDL-C remaining above the program's threshold (typically 70 mg/dL for ASCVD or 100 mg/dL for HeFH without ASCVD), and documentation of why the patient cannot reach goal on statins plus ezetimibe alone. The American College of Cardiology/American Heart Association 2018 Cholesterol Guideline states, "In patients with very high-risk ASCVD, if the LDL-C level remains 70 mg/dL or higher on maximally tolerated statin and ezetimibe therapy, adding a PCSK9 inhibitor is reasonable" [7].

Wisconsin Medicaid PA requests for Praluent are submitted through the ForwardHealth Portal. Approvals are typically valid for 12 months and require annual renewal with documentation of ongoing therapeutic need and LDL-C response. Denials can be appealed, and a strong appeal letter quoting ODYSSEY OUTCOMES outcomes data and the ACC/AHA guideline recommendation tends to support reversal.

Dual-eligible patients (Medicare plus Wisconsin Medicaid) face a different coverage path. Medicare Part D plans each set their own formulary for PCSK9 inhibitors, and Wisconsin Medicaid acts as secondary payer in most dual-eligible situations. The Medicare Part D coverage gap closed under the Inflation Reduction Act's redesign effective 2025, which caps out-of-pocket drug spending at $2,000 per year for Part D enrollees, offering meaningful relief for patients whose Part D plan covers Praluent [8].

Commercial Insurance and Step Therapy in Wisconsin

Commercial insurance plans sold in Wisconsin, including those on the ACA marketplace and employer-sponsored plans, almost universally place Praluent on a specialty tier requiring step therapy. Step therapy typically demands documented failure or intolerance of at least one, and more often two, statins at maximally tolerated doses, sometimes followed by ezetimibe failure as well.

Wisconsin enacted step therapy reform legislation that requires insurers to offer an exceptions process and respond within 72 hours for urgent requests [9]. Patients whose physicians submit a step therapy exception with ODYSSEY OUTCOMES data and the AHA cholesterol guideline citation have a meaningful basis for approval.

Major Wisconsin commercial payers including Anthem Blue Cross Blue Shield of Wisconsin, Quartz, Common Ground Healthcare Cooperative, and Molina Healthcare Wisconsin each publish their own formulary criteria. Physicians should check the current formulary year document directly on the plan's provider portal before submitting a PA, because criteria change annually. A cardiology or endocrinology specialty consult note citing LDL-C measurements and documented statin therapy history strengthens every commercial PA application.

The 2022 ACC Expert Consensus Decision Pathway on PCSK9 Inhibitors notes that "clinician-directed appeals, including peer-to-peer reviews, result in approval rates exceeding 80 percent when clinical criteria are clearly met" [10]. That figure gives prescribers in Wisconsin a concrete reason to pursue appeal rather than abandoning the medication after a first denial.

The Regeneron/Sanofi Praluent Savings Card in Wisconsin

Regeneron and Sanofi offer a copay savings card called MySavingsRx for commercially insured patients prescribed Praluent. Eligible Wisconsin patients with commercial insurance can pay as little as $0 per month through this program, subject to program terms and annual maximum benefit caps. The program is not available to patients whose primary coverage is a government program, including Wisconsin Medicaid, Medicare, or CHIP [11].

Enrollment takes less than five minutes at the Praluent patient support website or through the prescriber's office. The card works at participating specialty pharmacies and most major retail chains. Patients should confirm their specific pharmacy participates before submitting a prescription.

The savings card does not reduce the price billed to the insurance plan. It reduces only the patient's out-of-pocket share. Insurance companies cannot legally prohibit patients from using manufacturer assistance cards in Wisconsin, though some plans have experimented with accumulator adjustment programs that prevent copay card payments from counting toward a patient's deductible. Wisconsin patients using the MySavingsRx card should ask their specialty pharmacy whether their plan uses accumulator adjustments, because that affects total annual out-of-pocket exposure after the card's benefit is exhausted [12].

Is Compounded Alirocumab Legal in Wisconsin?

Compounded alirocumab is legally available in Wisconsin through state-licensed 503A compounding pharmacies operating under federal USP standards and Wisconsin Pharmacy Examining Board rules. A 503A pharmacy compounds medications for individual patients based on a valid prescription from a licensed prescriber. This is distinct from 503B outsourcing facilities, which compound for hospitals and clinics in larger batches.

Compounded versions of biologic monoclonal antibodies like alirocumab sit in a regulatory gray area at the federal level. The FDA has not placed alirocumab on its list of drugs that may not be compounded, so Wisconsin-licensed 503A pharmacies may compound it for individual patients with a legitimate clinical need [13]. The practical availability of 503A-compounded alirocumab varies because not every compounding pharmacy has the technical capacity to compound complex biologics.

When a Wisconsin physician evaluates a patient for compounded alirocumab, the decision framework should include four considerations: confirmation that the compounding pharmacy holds a valid Wisconsin Pharmacy Examining Board license, verification that the compounding facility follows USP Chapter 797 sterile compounding standards, a documented clinical rationale explaining why the commercial product is not suitable (commonly cost-driven inaccessibility), and a discussion with the patient about the absence of FDA-reviewed bioequivalence data for the compounded product [14].

Patients accessing compounded alirocumab through clinical research or expanded-access programs at institutions like UW Health or the Medical College of Wisconsin may pay little or nothing out of pocket. These pathways require physician referral and eligibility screening, and supply is limited. Standard compounding pharmacy pricing for compounded alirocumab in Wisconsin varies widely by pharmacy and is not published on a public database, unlike brand or generic small-molecule drugs [15].

How to Get the Lowest Praluent Cost in Wisconsin: A Step-by-Step Path

Start with insurance verification. Contact your Wisconsin insurer's pharmacy benefits line, get the prior authorization criteria in writing, and confirm which specialty pharmacies are in-network. Out-of-network specialty dispensing routinely adds 30 to 50 percent to out-of-pocket costs.

If insured commercially, apply for the Regeneron/Sanofi MySavingsRx savings card before filling the first prescription. The card can reduce monthly cost to $0 for eligible patients [11]. Apply online or ask your physician's office to enroll you during the visit.

If you are on Wisconsin Medicaid, have your prescriber submit a PA with complete documentation at first submission rather than submitting an incomplete request and waiting for denial. A complete submission includes LDL-C lab values from the past 90 days, the statin therapy record, and a clinical narrative referencing the ACC/AHA 2018 guideline [7].

If you are uninsured or the cost remains prohibitive, ask your prescribing physician whether a licensed 503A compounding pharmacy in Wisconsin can compound alirocumab for your prescription. Separately, ask whether UW Health Lipid Clinic or Milwaukee-area academic cardiology programs have any active alirocumab access programs or trials [16].

Wisconsin patients who are 65 or older and on Medicare Part D should verify whether their specific plan covers alirocumab on formulary. Under the 2025 Part D redesign, the $2,000 annual out-of-pocket cap applies [8]. A patient using Praluent for the full year under a covering Part D plan will spend no more than $2,000 total on all Part D drugs combined, which changes the calculus significantly compared with pre-2025 Part D structure.

Clinical Evidence Supporting Praluent Use in Wisconsin Patients

The evidence base for alirocumab is concentrated in two landmark trials. ODYSSEY OUTCOMES, published in the New England Journal of Medicine in 2018, enrolled 18,924 patients hospitalized for ACS within the prior 12 months and randomly assigned them to alirocumab 75 to 150 mg every two weeks (dose-adjusted to LDL-C target) or placebo on a background of high-intensity statin therapy. The primary outcome rate was 9.5 percent in the alirocumab group versus 11.1 percent in the placebo group over a median follow-up of 2.8 years (HR 0.85, P<0.001) [3]. The number needed to treat to prevent one major adverse cardiovascular event was approximately 64 over the trial period.

A pre-specified subgroup analysis of ODYSSEY OUTCOMES found the greatest absolute risk reduction in patients with LDL-C of 100 mg/dL or higher at baseline, reinforcing the guideline recommendation to prioritize PCSK9 inhibitor therapy for the highest-risk patients [3].

The ODYSSEY FH I and FH II trials, each with approximately 500 patients with HeFH, showed that alirocumab reduced LDL-C by 48 to 49 percent from baseline compared with placebo at 24 weeks (P<0.001), with 72 percent of alirocumab-treated patients reaching LDL-C below 70 mg/dL [17]. These figures directly support the PA documentation a Wisconsin Medicaid or commercial payer requires.

For patients with statin intolerance, the ODYSSEY ALTERNATIVE trial (N=314) compared alirocumab against ezetimibe and found alirocumab reduced LDL-C by 45 percent versus 15 percent with ezetimibe (P<0.001), with fewer muscle-related adverse events than atorvastatin rechallenge [18]. Citing ODYSSEY ALTERNATIVE data in a PA for a statin-intolerant Wisconsin patient provides direct clinical grounding for the request.

The ACC/AHA Guideline on the Management of Blood Cholesterol (2018) assigns a Class IIa recommendation (Level of Evidence A) to adding a PCSK9 inhibitor for very-high-risk ASCVD patients with LDL-C at or above 70 mg/dL despite maximally tolerated statin plus ezetimibe [7]. That evidence grade reflects data from more than 20,000 patients across the ODYSSEY and FOURIER programs.

Telehealth Prescribing of Praluent in Wisconsin

Wisconsin law permits licensed physicians, nurse practitioners, and physician assistants to prescribe Praluent via telehealth when a valid prescriber-patient relationship has been established. The Wisconsin Department of Safety and Professional Services does not require an in-person visit before a telehealth prescription for a non-controlled substance like alirocumab [19].

Telehealth prescribing of Praluent through HealthRX or other licensed Wisconsin telehealth providers requires at minimum a lipid panel from the past 12 months showing LDL-C elevation, documentation of prior statin therapy, a clinical history consistent with ASCVD or FH diagnosis, and a blood pressure reading. The prescriber completes a standard prior authorization on the patient's behalf, regardless of whether the visit was in-person or virtual.

For Wisconsin patients in rural areas, the northern lake region, the Fox Valley, or the Driftless Area, telehealth access to a lipid-focused clinician removes the barrier of driving 90 to 120 minutes to a metropolitan cardiology practice. Specialty pharmacy delivery then brings the medication to the patient's door once the insurance PA is approved. Lab work can be completed at a local Quest Diagnostics or LabCorp draw site with results transmitted electronically to the telehealth provider [20].